Assess whether a CMO finding is a delay or a refuse-to-file risk (f19112)

Situation

A literature paper the 505(b)(2) package leans on getting retracted put phase-3 protocol with endpoint-sensitivity issues in front of pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate. This Pharma & Life Sciences / Pharmacovigilance close is a CMO finding is from phase-3 protocol with endpoint-sensitivity issues, and the live options are A CMO finding is a delay, A refuse-to-file risk.

Decision

Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose A CMO finding is a delay / A refuse-to-file risk using phase-3 protocol with endpoint-sensitivity issues after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• The population in phase-3 protocol with endpoint-sensitivity issues is the one a literature paper the 505(b)(2) package leans on getting retracted named, so A CMO finding is a delay follows for this Pharmacovigilance file.
• The population in phase-3 protocol with endpoint-sensitivity issues is adjacent only to a literature paper the 505(b)(2) package leans on getting retracted; A refuse-to-file risk is the honest Pharma & Life Sciences call.
• A labeling team facing a boxed-warning debate already contained a literature paper the 505(b)(2) package leans on getting retracted before phase-3 protocol with endpoint-sensitivity issues arrived; no new Pharmacovigilance path.
• Provenance on phase-3 protocol with endpoint-sensitivity issues after a literature paper the 505(b)(2) package leans on getting retracted is broken; do not pick A CMO finding is a delay or A refuse-to-file risk yet.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim pharmacovigilance medical reviewer would keep.
• For this Pharma & Life Sciences Pharmacovigilance file, read phase-3 protocol with endpoint-sensitivity issues against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move a CMO finding is for pharmacovigilance medical reviewer.

Recommendation